Related Experiment Videos
Pharmacokinetics of recombinant interferon alpha-C
O Merimsky1, M Rubinstein, D Fischer
1Department of Oncology, Tel-Aviv Sourasky Medical Center, Israel.
Cancer Chemotherapy and Pharmacology
|January 1, 1991
Summary
This study evaluated recombinant interferon alpha-C (rIFN alpha-C) pharmacokinetics in renal-cell carcinoma patients. Intramuscular injection showed good bioavailability and sustained therapeutic levels for 24 hours.
Area of Science:
- Pharmacology
- Immunology
- Oncology
Background:
- Recombinant interferon alpha-C (rIFN alpha-C) is a novel alpha-interferon with high specific activity.
- Interferons are crucial in immune response and cancer therapy.
Purpose of the Study:
- To characterize the pharmacokinetic profile of intramuscularly administered rIFN alpha-C.
- To assess the bioavailability and serum concentration-time course of rIFN alpha-C in cancer patients.
Main Methods:
- 11 patients with metastatic renal-cell carcinoma received 10 million units of rIFN alpha-C intramuscularly.
- Serum interferon levels were measured up to 72 hours post-injection.
- Key pharmacokinetic parameters including Cmax, Tmax, AUC, and half-life were determined.
Main Results:
- Measurable serum IFN concentrations were observed as early as 0.5 hours post-administration.
- Peak serum levels (Cmax) were reached at 4-6 hours (53.2 +/- 4.6 units/ml).
- Sustained therapeutic levels persisted for 24 hours with an apparent half-life of 3-4 hours and a mean AUC of 1,259 +/- 145 units h ml-1.
Conclusions:
- Intramuscular administration of rIFN alpha-C demonstrates good bioavailability.
- The pharmacokinetic profile suggests sustained therapeutic drug levels, supporting its potential in cancer treatment.